Real-Life Outcome in Multiple Sclerosis in the Czech Republic

Figure 4

Progression to EDSS 4 by treatment group (unadjusted). The unadjusted analysis includes all treatment periods. Groups 0-2 are not significantly different, while group 3 appears to progress slower. However, the sample in group 3 is small (91 patients). txgrp 0 = no treatment; txgrp 1 = gammaglobulins, azathioprine, and cyclophosphamide; txgrp 2 = interferons and glatiramer acetate; txgrp 3 = natalizumab and fingolimod.